Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Feng Chi BiotechROCO:6744 -1.41%79 EV-to-EBIT is 4.18 as of Sep. 03, 2026, which is 21% below its 10-year median of 5.32. GuruFocus rates ROCO:6744 with a GF Score™ of 79/100 and a GF Value™ of NT$18.05 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 365 Biotechnology companies, Feng Chi Biotech ranks better than 70.14% on this metric.
Feng Chi Biotech (ROCO:6744) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Feng Chi Biotech's Enterprise Value for the quarter that ended in Jun. 2026 was NT$66.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Feng Chi Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$11.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Feng Chi Biotech EV-to-EBIT Related Terms
Feng Chi Biotech EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Feng Chi Biotech's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6744 vs VRTX, REGN, MRNA: EV-to-EBIT Comparison
For the Biotechnology subindustry, Feng Chi Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Feng Chi Biotech EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Feng Chi Biotech's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Feng Chi Biotech's EV-to-EBIT falls into.
Feng Chi Biotech's current Enterprise Value is NT$47.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Feng Chi Biotech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$11.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Feng Chi Biotech (ROCO:6744) has a EV-to-EBIT of 4.18 as of Sep. 03, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Feng Chi Biotech and its competitors. This is 21% below median its historical median of 5.32. Over the past decade, Feng Chi Biotech's EV-to-EBIT has ranged from 1.83 to 20.88. According to the industry distribution chart, Feng Chi Biotech ranks #109 out of 365 companies in the Biotechnology industry, placing it in the top 29.9%.
Is Feng Chi Biotech's EV-to-EBIT too high?
Feng Chi Biotech's current EV-to-EBIT of 4.18 is 21% below median its 10-year median of 5.32. Over the past 10 years, this metric has ranged from a low of 1.83 to a high of 20.88. The Biotechnology industry median EV-to-EBIT is 15.79. Feng Chi Biotech's value of 4.18 is 73.5% below this industry median. Based on the distribution chart, Feng Chi Biotech ranks #109 out of 365 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Feng Chi Biotech has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Feng Chi Biotech's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Feng Chi Biotech ranks #109 out of 365 companies for EV-to-EBIT. This puts Feng Chi Biotech in the upper half of its industry. The industry median EV-to-EBIT is 15.79. Feng Chi Biotech's value of 4.18 is 73.5% below this benchmark. Historically, Feng Chi Biotech's own EV-to-EBIT has ranged from 1.83 to 20.88 over the past decade. While the company's 10-year median is 5.32 vs. the industry median of 15.79, Feng Chi Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.79, based on 365 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Feng Chi Biotech's current EV-to-EBIT of 4.18 is 73.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Feng Chi Biotech and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Feng Chi Biotech's current EV-to-EBIT is 4.18, which is 21% below median its own 10-year median of 5.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Feng Chi Biotech stock overvalued right now?
Based on GuruFocus' analysis, Feng Chi Biotech (ROCO:6744) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$18.05, compared to a current price of NT$14.00 — trading 22.4% below its estimated fair value. The current EV-to-EBIT is 4.18, which is 21% below median its 10-year median of 5.32 and 73.5% below the Biotechnology industry median of 15.79. Feng Chi Biotech's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Feng Chi Biotech (ROCO:6744), the current EV-to-EBIT is 4.18 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Feng Chi Biotech (ROCO:6744) Overvalued in 2026?
Based on GuruFocus' analysis, Feng Chi Biotech stock appears to be undervalued.
The current stock price of NT$14.00 is trading 22.4% below its estimated GF Value™ of NT$18.05.
GuruFocus considers Feng Chi Biotech to be Modestly Undervalued.
Key valuation signals for ROCO:6744:
EV-to-EBIT: 4.18 (21% below median its 10-year median of 5.32)
GF Value™: NT$18.05 vs. price of NT$14.00 (22.4% below fair value)
Industry Position: 73.5% below the Biotechnology median (#109 of 365)
No single metric tells the full story. See the ROCO:6744 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Feng Chi Biotech Corp provide promotion and support for clinical testing and molecular genetic medicine research related technologies. The company's products and services include clinical testing, food testing, newborn screening, prenatal screening, iron stomach, interscience, and colony counting.
79GF Score
Get the complete analysis for ROCO:6744
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6744 has been successfully added to your 
